Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2020 · 10-Q
Revenue$1.24M$1.24M+38.8% vs Q2 2019 Net Income-$1.78M-$1.78MN/M vs Q2 2019 EPS Diluted-$0.13-$0.13N/M vs Q2 2019 Operating Income-$1,900,954N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-152.9%−51.1 pt vs Q2 2019
Net margin-143.5%−42.6 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 12, 2020 · 43 d after period end